Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
About Compugen (CGEN): Revolutionizing Cancer Immunotherapy with Computational Biology
Compugen Ltd. (NASDAQ: CGEN, TASE: CGEN) is a clinical-stage biotechnology company pioneering the use of computational discovery platforms to identify novel drug targets and develop next-generation cancer immunotherapies. Headquartered in Israel with offices in San Francisco, CA, Compugen leverages its proprietary Unigen™ platform, an AI/ML-powered predictive computational discovery engine, to decode complex cancer biology and uncover innovative therapeutic pathways. This unique approach positions Compugen at the forefront of the immuno-oncology field, where computational biology is transforming drug discovery and development.
Core Business Model and Revenue Streams
Compugen operates a hybrid business model that combines in-house drug development with strategic collaborations. Its primary revenue streams include milestone payments, royalties, and licensing agreements with leading pharmaceutical partners like Gilead Sciences and AstraZeneca. For example, its anti-IL-18 binding protein antibody, COM503 (licensed to Gilead), exemplifies the company's ability to advance novel therapies through early-stage development before transferring commercialization rights to partners. This model not only mitigates financial risk but also accelerates the path to market for its groundbreaking therapies.
Therapeutic Pipeline: Addressing Unmet Needs in Oncology
Compugen's therapeutic pipeline focuses on overcoming immune resistance mechanisms in cancer. Key assets include:
- COM701: A potential first-in-class anti-PVRIG antibody for solid tumors, showcasing durable responses in challenging cancer types.
- COM902: A potential best-in-class anti-TIGIT antibody, designed to enhance T-cell activation. This program is further validated through AstraZeneca's rilvegostomig, a PD-1/TIGIT bispecific antibody derived from COM902, currently in Phase 3 trials.
- COM503: A high-affinity anti-IL-18 binding protein antibody licensed to Gilead, aimed at unleashing the anti-tumor potential of IL-18 within the tumor microenvironment.
These programs are supported by Compugen's predictive discovery capabilities, which integrate multi-omics data, single-cell RNA sequencing, and spatial transcriptomics to identify novel therapeutic targets.
Unigen™ Platform: The Engine Behind Innovation
At the heart of Compugen's success is its Unigen™ platform, a flexible-loop computational system that combines advanced AI/ML algorithms with biological data to accelerate drug discovery. This platform has yielded multiple first- and best-in-class immuno-oncology targets, including PVRIG and TIGIT, and continues to fuel the company's pipeline and partnerships. By integrating patient-derived data and single-cell sequencing, Unigen enables a deeper understanding of tumor biology, paving the way for personalized cancer therapies.
Strategic Collaborations and Industry Validation
Compugen's partnerships with pharmaceutical giants like Gilead and AstraZeneca underscore the industry's recognition of its innovative capabilities. These collaborations not only provide financial stability through milestone payments and royalties but also validate the scientific rigor of its computational platform. For instance, AstraZeneca's advancement of rilvegostomig into multiple Phase 3 trials highlights the clinical potential of Compugen's discoveries.
Market Position and Competitive Advantage
Compugen stands out in the competitive biotech landscape due to its computational-first approach, which reduces the time and cost of drug discovery. Unlike traditional methods, its platform-driven strategy allows for the rapid identification of novel targets and mechanisms of action, providing a significant edge in the fast-evolving field of immuno-oncology.
Challenges and Future Outlook
While Compugen's innovative approach offers significant advantages, the company faces challenges typical of clinical-stage biotechs, including the inherent risks of drug development and dependence on external partnerships for commercialization. However, its robust pipeline, strategic collaborations, and financial runway into 2027 position it well for sustained growth and innovation.
Conclusion
Compugen Ltd. is redefining cancer immunotherapy through its computational discovery capabilities and innovative pipeline. With a strong focus on addressing unmet medical needs, the company is poised to make a lasting impact on the oncology landscape. Its unique blend of predictive science, clinical expertise, and strategic partnerships ensures a promising future in the fight against cancer.
Compugen Ltd. (Nasdaq: CGEN) announced the upcoming presentation of pre-clinical data on its lead asset, COM503, at the 20th CIMT Annual Meeting in Mainz, Germany, from May 3-5, 2023. COM503 is a first-in-class anti-IL18 binding protein antibody designed to inhibit cancer growth by releasing endogenous IL-18, which is crucial for activating NK and T cells in the tumor microenvironment. The company's plan includes filing an IND for COM503 in 2024.
The presentation, featuring high-affinity interactions of COM503 with IL-18 binding protein, aims to demonstrate enhanced anti-tumor activity while preserving peripheral immunity. Compugen's research highlights the potential of targeting cytokine biology in cancer treatment and positions COM503 as a transformative candidate within its broader immuno-oncology pipeline.
Compugen Ltd. (NASDAQ: CGEN) announced its upcoming presentation at the AACR annual meeting from April 14-19, 2023, in Orlando, Florida. The research focuses on the correction of the GENCODE gene model, which enables accurate detection of the novel target PVRIG. This advancement aims to enhance cancer immunotherapy research. Dr. Anat Cohen-Dayag emphasized the importance of single cell technology in understanding cancer biology. The presentation is scheduled for April 18, 2023, and will explore algorithms for gene model correction impacting PVRIG and TIGIT pathways. Compugen is advancing its product candidates, COM701 and COM902, targeting solid tumors.
Compugen Ltd. (Nasdaq: CGEN) will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:00 AM ET. The event will be held virtually, and interested parties can access a live webcast through the Investor Relations section of Compugen's website. A replay will be available for 90 days post-event. Compugen is focused on developing cancer immunotherapies, with notable candidates including COM701 and COM902. The company is headquartered in Israel and also has a presence in San Francisco, CA.
Compugen Ltd. (NASDAQ: CGEN) announced the dosing of the first patient in a proof-of-concept study evaluating a triple combination of COM701, COM902, and pembrolizumab for metastatic microsatellite stable colorectal cancer (MSS CRC). This follow-up to previous positive findings aims to assess the treatment's efficacy in patients with liver metastases who have undergone up to three lines of therapy. Initial findings are expected by the end of 2023. The study is based on earlier Phase 1 data showing anti-tumor activity with the dual combination of COM701 and nivolumab. Compugen continues to advance its immunotherapy pipeline with promising candidates.
Compugen Ltd. (CGEN) reported its financial results for Q4 and full-year 2022, highlighting significant progress in clinical studies, including upcoming triple combination studies targeting metastatic microsatellite stable colorectal cancer (MSS CRC) and platinum-resistant ovarian cancer (PROC). The company has approximately $83.7 million in cash, expected to fund operations through 2024. Revenues for Q4 were $7.5 million, increasing from $6 million in 2021. Total net loss for the year was $33.7 million. Notably, AstraZeneca's advancement of a related program triggered a $7.5 million milestone payment, validating Compugen's pipeline.
Compugen Ltd. (NASDAQ: CGEN) announced that AstraZeneca's bi-specific antibody, rilvegostomig, derived from Compugen's COM902, is set to progress into a Phase 3 trial in 2023. This trial will evaluate rilvegostomig's effectiveness as a PD-1/TIGIT bi-specific therapeutic. AstraZeneca is also expanding its Phase 2 program across various cancer indications. Compugen has received $10 million upfront and $15.5 million in milestone payments from AstraZeneca and is eligible for up to $200 million in additional milestones along with tiered royalties on future sales.
Compugen Ltd. (NASDAQ: CGEN) has announced a scheduled release of its fourth quarter and full year 2022 financial results on February 27, 2023, before the U.S. markets open. The management will conduct a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Interested parties can join the call via telephone or access the live webcast on the company's website. Compugen, based in Israel, specializes in cancer immunotherapy and predictive computational discovery, with product candidates COM701 and COM902 targeting solid tumors, and a partnered program with AstraZeneca in Phase 2 development.
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced its upcoming presentation at the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET. The event will be held virtually, and a live webcast will be accessible through the Investor Relations section of Compugen's website, with a replay available afterward.
Compugen is pioneering computational target discovery for cancer immunotherapies, with product candidates like COM701 and COM902. The company also has a partnered program, AZD2936, in Phase 2 development by AstraZeneca.
Compugen Ltd. (NASDAQ: CGEN) announced its participation in the JMP Securities C-Suite Series, scheduled for January 30, 2023, at 11:00 am ET. CEO Anat Cohen-Dayag and other management team members will discuss the company's advancements in the DNAM-1 axis. A live webcast of the event will be available on Compugen's Investor Relations webpage, with a replay accessible afterward. Compugen specializes in cancer immunotherapies and has developed several promising product candidates, including COM701 and COM902 for solid tumors, with ongoing collaborations such as the AZD2936 program with AstraZeneca.
Compugen Ltd. (CGEN) reported encouraging results for its COM701 therapy combined with nivolumab ± BMS-986207 in heavily pretreated patients with platinum-resistant ovarian cancer. The study showed a 20% overall response rate and a disease control rate of 45%. Notably, three patients on triplet therapy have maintained responses for over nine months. The therapy demonstrated effectiveness across various cancer types, particularly in high-grade serous adenocarcinoma. Compugen plans to pursue further studies to enhance data supporting these findings.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
What is Compugen's core business focus?
How does Compugen generate revenue?
What is the Unigen™ platform?
What are Compugen's key therapeutic candidates?
Who are Compugen's major partners?
What differentiates Compugen from other biotech companies?
What is rilvegostomig, and how is it related to Compugen?
What are the risks associated with Compugen's business model?
What is the significance of the COM503 program?
What is Compugen's financial outlook?
